Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
eRapa (encapsulated rapamycin)
DRUG
3 trials
Sponsors
Rapamycin Holdings, Inc. dba Emtora Biosciences
, Rapamycin Holdings Inc.
, Biodexa Pharmaceuticals
Conditions
Familial Adenomatous Polyposis (FAP)
Prostate Cancer
Phase 1
Trial of eRapa in Prostate Cancer Patients
Completed
NCT03618355
Rapamycin Holdings, Inc. dba Emtora Biosciences
Prostate Cancer
Start: 2018-08-28
End: 2019-12-02
Updated: 2020-03-31
Phase 3
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
Recruiting
NCT06950385
Rapamycin Holdings Inc.
Familial Adenomatous Polyposis (FAP)
Start: 2025-07-18
End: 2031-01-01
Target: 168
Updated: 2026-06-02
Unknown Phase
Expanded Access to 0.5 mg eRapa for Familial Adenomatous Polyposis
NCT07689942
Biodexa Pharmaceuticals
Familial Adenomatous Polyposis (FAP)
Updated: 2026-07-08
Related Papers
Results of a phase Ib trial of encapsulated rapamycin in prostate cancer patients under active surveillance to prevent progression.
Journal of Clinical Oncology
2020-02-04
7 citations